Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PPARG | P37231 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | FABP2 | P12104 | 2/20 | 0.60 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16577214 | 0.92 | PPARA (0.74) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL11800181 | 0.83 | PPARA (0.58) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL9372364 | 0.82 | PPARA (0.72) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| Clofibric Acid SCHEMBL102826 | 0.82 | PPARA (1.00) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL135713 | 0.82 | PPARA (0.72) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL10867374 | 0.82 | PPARA (0.72) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| Clofibric Acid SCHEMBL2227936 | 0.82 | PPARA (1.00) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL9590308 | 0.81 | PPARA (0.70) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| Clofibric Acid SCHEMBL10634899 | 0.81 | PPARA (0.96) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL11643674 | 0.81 | PPARA (0.70) | PPARACYP1A2CYP3A4CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403857-B2 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-9198429-B2 | Heterocyclic alkanol-derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9198429-B2 | Heterocyclic alkanol-derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9198429-B2 | Heterocyclic alkanol-derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2015-03-19 | — | — | US | disclosed |
| EP-2782904-A1 | NOVEL HETEROCYCLIC ALKANOL-DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2014-10-01 | — | — | EP | disclosed |
| US-20140274952-A1 | NOVEL HETEROCYCLIC ALKANOL-DERIVATIVES | BAYER INTELLCTUAL PROPERTY GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140274952-A1 | NOVEL HETEROCYCLIC ALKANOL-DERIVATIVES | BAYER INTELLCTUAL PROPERTY GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140274952-A1 | NOVEL HETEROCYCLIC ALKANOL-DERIVATIVES | BAYER INTELLCTUAL PROPERTY GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| WO-2013076227-A1 | NOVEL HETEROCYCLIC ALKANOL-DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013076227-A1 | NOVEL HETEROCYCLIC ALKANOL-DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | FABP4, GYS2, FABP2 | PPARA 1082/4885CYP1A2 169/4885CYP3A4 276/4885 |
| US-20140274952-A1 | NOVEL HETEROCYCLIC ALKANOL-DERIVATIVES | ERG28, CBR3, MYB | PPARA 456/4885CYP1A2 502/4885CYP3A4 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.